Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit
On Friday, September 24, 2021, Eli Lilly announced the voluntary recall of one lot of Glucagon Emergency Kits to the consumer/user level.
Lilly is recalling lot D239382D, Expiration April 2022 because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. An investigation indicated that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
What to Do:
Check to see if your Glucagon Emergency Kit is affected by this recall. The lot number can be found on the label of the kit as well as the vial.
Consumers in possession of Glucagon Emergency Kit lot D239382D should contact The Lilly Answers Center at 1-800-LILLYRX (1-800-545-5979) for return and replacement instructions for the product (hours of operation are Monday- Friday, 9AM – 7PM EST) and should contact their health-care provider for guidance. Consumers should contact their physician or health-care provider if they have experienced any problems that may be related to taking or using this product.
If your Glucagon is not part of the lot, but is expired, use this opportunity to contact your health-care provider to refill your prescription.
Whether or not your glucagon kit is expired or affected, you might consider upgrading to a newer, easier to use form of glucagon, whether it be nasal glucagon from Lilly or auto-injector pens from Xeris or Zealand.
Glucagon is a hormone that tells your liver to release its stored sugar (also known as glycogen) into your bloodstream. Emergency glucagon treatments can raise your blood sugar during severe hypoglycemia.
Anyone who takes insulin (or another medication that can cause low blood sugars) should have an unexpired emergency glucagon treatment.
To learn more about emergency glucagon, visit Emergency Glucagon: Everything You Need to Know
This content mentions Lilly Diabetes, an active partner of Beyond Type 1.
News coverage by the Beyond Type 1 team is operated independently from any content partnerships. Beyond Type 1 maintains full editorial control of all content published on our platforms.